
Gilead Sciences Inc, which has its headquarters at Foster City in California, is likely to increase the price of its next generation version of Hepatitis C drug that is to be released into the international market during October. The American biotech company that develops and also commercializes therapeutics is already under fire for its $84,000 cost of hepatitis C drug. The new version of drug is going to be even more expensive. Ever since the release of this information, Gilead's stock … [Read more...]